How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis
Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.
Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing
Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.
Cancer Care in 2021 and Beyond: Catalytic Trends, Entrants, and Developments to Optimize Care During and Post Pandemic
Cancer care has been disproportionately impacted by the COVID-19 pandemic, possibly leading to later-stage cancers and increasing patient morbidity and mortality, as well as regression in the strides made in cancer care and overall patient survival. The oncology ecosystem is determined to do all it can to not only prevent these regressions but also to accelerate further advancements. Precision’s Elizabeth Oyekan outlines 10 observed trends and developments to further optimize cancer care in 2021 and beyond.
Medicine’s Evolution Has Brought Novel New Products, Opportunities for Pharma
The rise of innovative new therapeutic interventions means that payers need more information than ever to properly assess treatments, as well as compare them with existing methods of care. They also can benefit from collaborations with manufacturers, including on innovative pricing models. Precision’s Reta Mourad joins other experts for a discussion of the opportunities and challenges facing payers as they confront antiquated reimbursement models and work to develop new payment models that include therapeutic value assessments.
We Have Vaccines, Now What? How to Ensure Continued COVID-19 Vaccine Discovery and Expedite Access
In December 2020, the FDA granted emergency use authorization for two COVID-19 vaccines. And although there were more than 20 other vaccine candidates undergoing phase 2 or 3 testing as of January 2021, there is more work to be done. Precision’s Marlon Graf and Rifat Tuly identify two components that are required for continued success with COVID-19 vaccine policies, and discuss ways to address them to ensure that the discovery and development of new vaccines for COVID-19 and future pandemics can be sustained in the future.
Project Farma: Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy
The cell and gene therapy manufacturing skills shortage is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing learning and development costs. Project Farma’s Gail Dutton discusses the impact of the cell and gene therapy manufacturing skills shortage, and reviews ways to scale up and bring more therapies to commercialization despite the skills gap.
Socially Stabilizing Science During the Infodemic
Pharmaceutical manufacturers have accelerated innovation to create vaccines in record time, yet the US is lagging in leveraging effective messages to generate enthusiasm for COVID-19 vaccine adoption. Precision’s Maureen Hennessey and Pam Caputo discuss how using the sacred patient-clinician relationship can help combat the infodemic of vaccine misinformation and disinformation.
COVID-19: Models, Mathematics, and Myths
Researchers have introduced mathematical models of varying complexity over the past several months to capture different aspects of COVID-19’s dynamics, with limited to no implications for healthcare decision-makers. Why? Precision’s Anuj Mubayi and Ross Maclean identify the five myths surrounding COVID-19 mathematical models, and share potential answers regarding the extent to which each myth is addressed in the existing models.
Gene Therapy for Rare Disorders Conference
Are you attending the Gene Therapy for Rare Disorders virtual conference this year? Make sure you stop by to check out our booth between February 22-25, and schedule time to chat with our experts!
With 20 Biosimilars Available, U.S. Market Is Heating Up
In an October 2020 healthcare industry report, the authors projected that biosimilars could hit $80 billion in aggregate sales and provide savings in excess of $100 billion in aggregate over the next five years. Precision’s Dan Danielson joins other industry experts to discuss the impact of biosimilars in 2020 and the forecast for the biosimilars landscape going forward.